Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates.
Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium.
For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register.
For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.

Patent details

2024C546 Product name: odronextamab

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic information

Application number:
2024C/546
Type:
Certificate
SPC type:
Medical
Basic patent number:
191886936
Status:
Open & Published
Publication number:
2024C546
1rst applicant's nationality:
Procedural language:
Dutch

Marketing authorization

Marketing authorization number:
EU/1/24/1843
Marketing authorization type:
National/EU
Designates country:
No
Marketing authorization date:
23/08/2024
Marketing authorization status:
Claimed
Marketing authorization country:
Belgium (BE)

Dates

Filing date:
09/12/2024
First marketing authorization date:
23/08/2024
Grant date:
Activation date:
BE Publication date:
12/12/2024
Lapsed date:
Expiration date (if granted and all annual fees paid):
Basic SPC Expiration (if granted and all annual fees paid):
23/08/2039
SPC/SPC Extension Expiration (if granted and all annual fees paid):
Rejection date:
Withdrawal date:

Applicant

Name:
Regeneron Pharmaceuticals, Inc.
Legal Form:
Inc.
From:
09/12/2024
Address:
777 Old Saw Mill River Road, Tarrytown NY 10591, United States (US)
To:

Agent

Name:
NLO
Legal Form:
From:
10/12/2024
Address:
New Babylon City Offices Anna van Buerenplein 21A, 2595 DA DEN HAAG, Netherlands (NL)
To:

Publication

Bulletin

Bulletin heading:
SPC
Journal edition number:
2024/23
Publication date:
27/12/2024
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates
Filing date Document type Publication Type Document Description Number of pages File Type
09/12/2024 Application Form 4 PDF /2/3/3/1/9/0722491332/docs/2024c546_0_applicationform_20241210_084528590.pdf
12/12/2024 Publication I1 1 PDF /2/3/3/1/9/0722491332/docs/2024c546_1_i1document_20241212_122928413.pdf
09/12/2024 Abstract Product Characteristics Abstract of the characteristics of the product 58 PDF /2/3/3/1/9/0722491332/docs/2024c546_2_abstractproductcharacteristics_20241210_084528217.pdf
09/12/2024 General Document Other 21 PDF /2/3/3/1/9/0722491332/docs/2024c546_3_generaldocument_20241210_084527493.pdf
09/12/2024 Marketing Authorization 1st Marketing Authorization (EU) 4 PDF /2/3/3/1/9/0722491332/docs/2024c546_4_marketingauthorization_20241210_084527275.pdf
09/12/2024 MA Official Publication Official Publication of 1st Marketing Authorization 11 PDF /2/3/3/1/9/0722491332/docs/2024c546_5_maofficialpublication_20241210_084528392.pdf
19/12/2024 Outgoing Correspondence 2 PDF /2/3/3/1/9/0722491332/docs/2024c546_6_outgoingcorrespondence_20241224_084709144.pdf